Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585726 · ClinicalTrials.gov registry record · NA
Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)
A NA study, sponsored by Lake Washington Vascular.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT02585726 is a NA study that has completed, run by Lake Washington Vascular. The registered enrollment target is 50 participants.
The verdict
NCT02585726, a NA study, has completed, sponsored by Lake Washington Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS).
Interventions
- DEVICE SP-402 VenaSeal™ Closure System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02585726
The ClinicalTrials.gov registry entry for NCT02585726 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lake Washington Vascular, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SP-402 VenaSeal™ Closure System is the first listed.
NCT02585726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02585726 about?
NCT02585726 is a clinical study titled "Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)". The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic veno...
What is the current status of trial NCT02585726?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-10. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02585726?
The interventions under investigation include: SP-402 VenaSeal™ Closure System (DEVICE).
Who is sponsoring clinical trial NCT02585726?
This trial is sponsored by Lake Washington Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.